Kyntra Bio to Report Fourth Quarter and Full Year 2025 Financial Results

Core Viewpoint - Kyntra Bio, formerly known as FibroGen, is set to announce its fourth quarter and full year 2025 financial results on March 16, 2026, after market close, followed by a conference call to discuss corporate and financial performance [1]. Financial Results Announcement - The financial results will be announced on March 16, 2026, after market close [1]. - A conference call will take place on the same day at 5:00 PM Eastern Time to provide further details [1][2]. Company Overview - Kyntra Bio is a biopharmaceutical company focused on developing novel therapies in oncology and rare diseases [3]. - Roxadustat (EVRENZO™) is approved in Europe, Japan, and other countries for treating anemia in chronic kidney disease patients, both on and off dialysis [3]. - The company is evaluating a Phase 3 trial for roxadustat in anemia associated with lower-risk myelodysplastic syndromes in the U.S. [3]. - FG-3246 (FOR46), a first-in-class antibody-drug conjugate targeting CD46, is in Phase 2 development for metastatic castration-resistant prostate cancer [3]. - The development program also includes FG-3180, a CD46-targeted PET biomarker [3].